Today’s economic environment and regulatory pressures demand that medical technology manufacturers do more with their existing U.S. facilities. Margin pressures from reimbursement rates, coupled with supply chain disruptions in specialized raw materials and sterile packaging, are forcing leaders to improve productivity without compromising compliance.
There are four main reasons MedTech manufacturers are considering productivity improvement efforts.
One lever companies are pulling to increase productivity is to invest in capital improvements. However, they may want to reconsider capital investments as the first solution. Capital as a response has made sense for most of the last 15 years. It has been cheap, with the weighted-average cost of capital (WACC) for the average S&P 500 company just under 6 percent. But, between rises in the cost of debt and cost of equity capital, the WACC is now more than 10 percent.
Before investing in capital improvements, competitive MedTech firms are focused instead on getting more out of their existing assets, trained team members, and compliant systems. Naturally, improved throughput can lower COGS, reduce overtime, and even increase revenue if your plant is over-scheduled. What’s more, companies can unlock hidden capacity and improve working capital through some relatively small investments in time and expense:
Yes, you’ll probably need to invest in capital eventually. But the most competitive companies are first maximizing the combination of their existing validated assets, talent, compliant processes, and advanced software. Your board, executive team, and employees will appreciate the jump in profitability and resilience. And regulators and patients will value the enhanced reliability.
"*" indicates required fields